We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+20.44%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$476M
AUM Growth
-$38.3M
(-7.4%)
Cap. Flow
-$67.9M
Cap. Flow
% of AUM
-14.26%
Top 10 Holdings %
Top 10 Hldgs %
34.45%
Holding
94
New
29
Increased
20
Reduced
12
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$16.4M |
| 2 |
Quest Diagnostics
DGX
|
+$14.4M |
| 3 |
Cigna
CI
|
+$14.2M |
| 4 |
Universal Health Services
UHS
|
+$11.8M |
| 5 |
Intuitive Surgical
ISRG
|
+$10.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$16.2M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$14.4M |
| 3 |
Boston Scientific
BSX
|
+$13.6M |
| 4 |
Biogen
BIIB
|
+$13.3M |
| 5 |
CVS Health
CVS
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Cytokinetics
CYTK
$10.7B
| $18.3M | 3.85% |
400,000
-56,300
| -12% | -$2.42M |
|
|
2
Cytokinetics
CYTK
$10.7B
| $18.3M | 3.85% |
400,000
+50,000
| +14% | +$2.15M |
|
|
3
Moderna
MRNA
$22.8B
| $18M | 3.77% |
+100,000
| New | +$16.4M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.7B
| $17.6M | 3.69% |
170,000
+63,000
| +59% | +$5.91M |
|
5
Merck
MRK
$316B
| $16.6M | 3.49% |
150,000
-35,000
| -19% | -$3.58M |
|
|
6
Quest Diagnostics
DGX
$25.8B
| $15.6M | 3.28% |
+100,000
| New | +$14.4M |
|
7
Inspire Medical Systems
INSP
$1.85B
| $15.1M | 3.17% |
60,000
+20,000
| +50% | +$4.26M |
|
8
Zentalis Pharmaceuticals
ZNTL
$331M
| $15.1M | 3.17% |
750,000
+200,000
| +36% | +$4.3M |
|
|
9
Cigna
CI
$72.4B
| $14.9M | 3.13% |
+45,000
| New | +$14.2M |
|
10
PUT
Madrigal Pharmaceuticals
MDGL
$11.7B
| $14.5M | 3.05% |
+50,000
| New | +$4.89M |
|
|
11
Universal Health Services
UHS
$10.2B
| $14.1M | 2.96% |
+100,000
| New | +$11.8M |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $13.7M | 2.88% |
360,000
+3,000
| +0.8% | +$115K |
|
|
EXAS
13
DELISTED
Exact Sciences
EXAS
| $13.6M | 2.86% |
275,000
+125,000
| +83% | +$5.11M |
|
14
Guardant Health
GH
$21.4B
| $12.9M | 2.71% |
475,000
+25,000
| +6% | +$1.14M |
|
15
Elevance Health
ELV
$82B
| $12.8M | 2.69% |
25,000
-15,000
| -38% | -$7.62M |
|
16
uniQure
QURE
$3.03B
| $12.5M | 2.62% |
550,000
+117,000
| +27% | +$2.52M |
|
|
17
Intuitive Surgical
ISRG
$130B
| $11.7M | 2.45% |
+44,000
| New | +$10.7M |
|
18
HCA Healthcare
HCA
$86.8B
| $10.3M | 2.17% |
+43,000
| New | +$9.63M |
|
19
Gilead Sciences
GILD
$168B
| $10.3M | 2.16% |
+120,000
| New | +$9.5M |
|
20
Sanofi
SNY
$102B
| $9.69M | 2.03% |
200,000
-50,000
| -20% | -$2.19M |
|
21
AstraZeneca
AZN
$241B
| $9.49M | 1.99% |
+70,000
| New | +$8.78M |
|
22
Relay Therapeutics
RLAY
$4.26B
| $9.34M | 1.96% |
625,000
+25,000
| +4% | +$479K |
|
23
Krystal Biotech
KRYS
$9.61B
| $9.11M | 1.91% |
115,000
+25,000
| +28% | +$1.86M |
|
24
Alnylam Pharmaceuticals
ALNY
$29.3B
| $8.32M | 1.75% |
35,000
-35,000
| -50% | -$7.47M |
|
25
Zimmer Biomet
ZBH
$18.5B
| $8.29M | 1.74% |
+65,000
| New | +$7.54M |
|
Similar funds
CL
ACM
NSCM
ACG
NSUP
TP
ACP
TA
Integral Health Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Integral Health Asset Management held 94 positions worth $476M, down 7.4% from $515M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Integral Health Asset Management withdrew a net $67.9M in Q4 2022, closing 33 positions and reducing 12 holdings. Its most notable exit was Baxter International, an estimated $16.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier.
Against the trend, Integral Health Asset Management opened a new position in Moderna worth $18M.
- Integral Health Asset Management's largest Q4 2022 buy was Moderna: 100,000 shares worth $18M.
- Integral Health Asset Management added most to BioMarin Pharmaceuticals in Q4 2022, an estimated $5.91M increase.
- Integral Health Asset Management's biggest Q4 2022 reduction was Envista, cutting an estimated $11.6M.
- Integral Health Asset Management fully exited Baxter International in Q4 2022, selling an estimated $16.2M.
- Integral Health Asset Management's ten largest holdings make up 34% of its $476M portfolio in Q4 2022.
- Integral Health Asset Management opened 29 new positions and closed 33 in Q4 2022.
- Integral Health Asset Management's portfolio value fell 7.4% quarter-over-quarter to $476M.
Based on Integral Health Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.